OncoMatch/Clinical Trials/NCT06475326
Adebrelimab in Combination With NALIRIFOX in Locally Advanced Pancreatic Cancer
Is NCT06475326 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments for pancreatic cancer.
Treatment: Adebrelimab · Oxaliplatin 100 MG · Irinotecan liposome · Calcium Folinate · Fluorouracil — In this study, Adebrelimab combined with NALIRIFOX conversion therapy was performed in subjects with locally advanced pancreatic cancer to evaluate the efficacy and safety of conversion therapy with immunotherapy combined with chemotherapy, followed by different treatment methods such as surgery, continued conversion therapy, and advanced systemic therapy according to different transformation outcomes, to improve the survival benefit of subjects with locally advanced pancreatic cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Pancreatic Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: radiotherapy
Have not received previous treatment for pancreatic cancer, including radiotherapy, chemotherapy, surgery, etc
Cannot have received: chemotherapy
Have not received previous treatment for pancreatic cancer, including radiotherapy, chemotherapy, surgery, etc
Cannot have received: surgery
Have not received previous treatment for pancreatic cancer, including radiotherapy, chemotherapy, surgery, etc
Lab requirements
Blood counts
WBC ≥3.0×10^9/L; ANC≥1.5×10^9/L; PLT≥100×10^9/L; HGB≥90 g/L
Kidney function
Cr≤1.5×ULN or CrCl ≥60 mL/min
Liver function
AST≤2.5×ULN; ALT≤2.5×ULN; TBIL≤1.5×ULN; Total bilirubin ≤ 2 mg/dL (subjects with bile duct stents can be enrolled if bilirubin ≤ 2 mg/dL and no cholangitis after stent placement)
Cardiac function
No obvious abnormality in ECG
laboratory tests with adequate organ function: Blood routine: WBC ≥3.0×10^9/L; ANC≥1.5×10^9/L；PLT≥100×10^9/L； HGB≥90 g/L; Liver function: AST≤2.5×ULN; ALT≤2.5×ULN； TBIL≤1.5×ULN; Renal function: Cr≤1.5×ULN or CrCl ≥60 mL/min; Coagulation function: INR≤1.5, APTT≤1.5×ULN ; There was no obvious abnormality in ECG.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify